Citations

Mayo Clinic

Clear

88156 citation(s) found for "NA".

Insulin autoimmune hypoglycemia unmasking monoclonal gammopathy in type 2 diabetes
Prasad, S. , Sharma, A K , Parmar, Vidhi, Jindal, Tanisha , Kothia, Darpan, Bavaria, Deep, Prasad, Sai , Kothia, Darpan

JCEM Case Reports | July 13, 2026 | Volume: 4 | Issue: 8 | Pages: No page available

10.1210/jcemcr/luag190 | PMID 42438805 Get It

Abstract Insulin autoimmune syndrome (IAS), also known as Hirata disease, is a rare cause of spontaneous hypoglycemia due to circulating insulin autoantibodies, most commonly described in East Asian individuals and those exposed to sulfhydryl-containing drugs. We describe a 58-year-old South Asian man with type 2 diabetes mellitus who presented with recurrent fasting and postprandial hypoglycemia despite cessation of all glucose-lowering medications. A spontaneous episode confirmed Whipple triad: plasma glucose 38 mg/dL (SI: 2.1 mmol/L; reference range, 70-99 mg/dL [SI: 3.9-5.5 mmol/L]), markedly elevated serum insulin at 156 µIU/mL (SI: 1083 pmol/L; reference range, 2.6-24.9 µIU/mL [SI: 18-173 pmol/L]), and C-peptide of 5.8 ng/mL (SI: 1.9 nmol/L; reference range, 0.5-2.0 ng/mL [SI: 0.17-0.66 nmol/L]), with a negative sulfonylurea screen and markedly elevated insulin autoantibody titers. Polyethylene glycol precipitation confirmed antibody-bound insulin sequestration. Workup identified IgG-kappa monoclonal gammopathy of undetermined significance as the probable precipitant. Dietary modification, oral glucocorticoids, and acarbose achieved near-complete resolution of hypoglycemia with declining autoantibody titers over 4 weeks. This case highlights the importance of considering IAS in unexplained hyperinsulinemic hypoglycemia and the need to screen for plasma cell dyscrasias in atypical presentations.
Prognostic Factors in Primary Head and Neck Cutaneous Squamous Cell Carcinoma: A Large‐Scale, Multi‐Institutional Competing‐Risks Analysis
Girardi, Fábio Muradás , Machado, Cristian David Cardona, Wysong, Ashley, Ran, Nina A., Granger, Emily , Koyfman, Shlomo A. , Vidimos, Allison T. , Carr, David R., Shahwan, Kathryn T. , Hirotsu, Kelsey E. , Carter, Joi B., Mangold, Aaron R., Srivastava, Divya, Brodland, David G., Zitelli, John A., Willenbrink, Tyler J., Jambusaria‐Pahlajani, Anokhi , Nijhawan, Rajiv I. , Ruiz, Emily S., Cañueto, Javier , Granger, Emily E , Willenbrink, Tyler J , Wysong, Ashley , Carr, David R., Carucci, John A. , Mangold, Aaron R. , Srivastava, Divya , Zitelli, John A. , Ruiz, Emily S.

Journal of Surgical Oncology | July 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jso.70325 | PMID 42437512 Get It

ABSTRACT Background Current staging systems for head and neck cutaneous squamous cell carcinoma (HNCSCC), such as AJCC8 and BWH, often fail to adequately stratify high‐risk patients, particularly due to the exclusion of important biological and host factors. This study aimed to identify independent prognostic factors for HNCSCC outcomes in the largest multi‐institutional retrospective series to date. Methods De‐identified data from 8,610 primary HNCSCC tumors, treated with curative intent surgery across multiple international centers, were analyzed. Outcomes included local recurrence (LR), locoregional metastasis (LM), distant metastasis (DM), and disease‐specific death (DSD). Multivariable Fine–Gray subdistribution hazard regression models with robust standard errors clustered at the patient level were fitted to generate exploratory hypotheses regarding independent hazard determinants. Results During a median follow‐up of 31.4 months (IQR 14.2–52.8), the cumulative incidence was 3.3% for LR, 2.7% for LM, 0.5% for DM, and 1.2% for DSD. Multivariable analysis confirmed that tumor diameter, poor differentiation, deep invasion, and large‐caliber perineural invasion (LCPNI) were the strongest predictors, being significantly associated with at least three of the four outcomes. Notably, factors currently excluded from or weighted differently in staging systems also proved critical: Immunosuppression was significantly associated with LR (SHR 2.03) and DSD (SHR 1.70); and lymphovascular invasion (LVI) was independently associated with LM (SHR 3.00). Poor differentiation demonstrated high prognostic impact, being a significant predictor for all four endpoints. Conclusion Tumor diameter, poor differentiation, deep invasion, LCPNI, immunosuppression status, and LVI are the most critical independent factors for HNCSCC prognosis. Our multi‐institutional data provide a robust framework for hypothesis generation, highlighting that incorporating host biological features and non‐anatomic variables could significantly refine future staging system discussions.
Shared lipidome and proteome signatures of frontotemporal lobar degeneration and Alzheimer’s disease
Ambaw, Yohannes, Nana, Alissa, Li, Zhuoning , Singh, S , Monetti, Mara , Miller, Bruce L, Spina, Salvatore, Seeley, William W, Farese, Robert, Ambaw, Yohannes Abere , Nana, Alissa , Spina, Salvatore , Grinberg, Lea T. , Seeley, William W. , Walther, Tobias C. , Farese, Robert V.

No container title available | July 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.11.737778 | PMID 42465421 Get It

Abstract Frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD) differ in their clinical features and genetic etiologies but share progressive cognitive decline. Emerging evidence implicates lipid dysregulation in neurodegeneration, but its extent across FTLD subtypes and how it compares to AD are unclear. Here, we performed integrated lipidomic and proteomic analyses of matched frontal (disease-vulnerable) and occipital (relatively spared) post-mortem cortices from individuals with genetic and sporadic FTLD-TDP, FTLD-tau (Pick’s disease, PiD), AD, and controls. FTLD and AD exhibited convergent lipid alterations, including reduced levels of cardiolipins and phosphatidylethanolamines, alongside increased gangliosides, diacylglycerols, cholesterol esters, acylcarnitines, and coenzyme Q, with generally greater changes in FTLD frontal cortex. FTLD displayed additional alterations, including reductions in bis(monoacylglycerol)phosphate, ceramides, phosphatidylserines, phosphatidylinositols, and sulfatides. These lipid changes were accompanied by proteomic alterations involving lysosomal proteins, phospholipases, phospholipid remodeling enzymes, and fatty acid oxidation pathways. Although lipidomic and proteomic signatures were broadly shared across FTLD subtypes, GRN associated FTLD-TDP and PiD showed the most extensive alterations. Triglycerides were selectively reduced in PiD in association with decreased DGAT1 expression, whereas cholesterol esters were elevated across all subtypes except C9orf72 associated FTLD-TDP. These findings identify shared disruptions in lipid homeostasis and lysosomal lipid metabolism across FTLD and AD, highlighting convergent metabolic pathways underlying neurodegeneration.
Endoscopic Ultrasound-Guided Gastroenterostomy for Gastric Outlet Obstruction: A Comparison of Duodenal Versus Jejunal Placement on Patient Outcomes
Khan, Rishad , Law, Ryan , Guralwar, Chinmay , Bauss, Jacob, Suman, Garima , Han, S, Buttar, Navtej, Song, Louis–Michel Wong Kee, Law, Ryan J, AbiMansour, Jad P. , Vargas, Eric J , Wong Kee Song, Louis-Michel, Storm, Andrew C , Chandrasekhara, Vinay , Bauss, Jacob M. , Han, Samuel, Vargas, Eric J. , Dayyeh, Barham K. Abu , Buttar, Navtej , Storm, Andrew C. , Chandrasekhara, Vinay

Endoscopy International Open | July 11, 2026 | Volume: 14 | Issue: CP | Pages: No page available

10.1055/a-2913-6628 | PMID 42583363 Get It

Abstract Background and Aims EUS-guided gastroenterostomy (EUS-GE) is an effective option to palliate symptoms of gastric outlet obstruction (GOO). While the jejunum is conventionally targeted (EUS-GJ), targeting the duodenum (EUS-GD) may offer clinical advantages. Outcomes were compared for EUS-GJ and EUS-GD. Methods Adult patients who underwent EUS-GE for GOO between 2020 and 2024 were included and categorized as an EUS-GD if the stent entered the transverse or ascending duodenum or an EUS-GJ if the stent entered more distally. The primary outcome was clinical success (soft diet tolerance at 7 days). Secondary outcomes included adverse events (AEs), stent misdeployment, and unplanned endoscopic reintervention. Baseline demographic variables and outcomes were compared with statistical significance at p < 0.05. Results Of the 139 included patients (median age 67 years (IQR 61–74); 41% female), 105 underwent EUS-GJ and 34 underwent EUS-GD. Clinical success was 98% for EUS-GJ and 94% for EUS-GD (p = 0.25). The misdeployment rate was 7% for EUS-GJ and 0% for EUS-GD (p = 0.19). The AE rate was 22% for EUS-GJ and 12% for EUS-GD (p = 0.23). There were no significant differences for stent obstruction (EUS-GJ 12% vs. EUS-GD 6%), bleeding (2% vs. 6%), perforation (4% vs. 0%), stent migration (1% vs. 0%), infection (3% vs. 0%), and unplanned reintervention (14% vs. 9%). Conclusion Both EUS-GJ and EUS-GD demonstrate high clinical success with no significant differences in adverse event rates. These data can support intraprocedural decision-making for endoscopists performing EUS-GE.
Comparing Harmonization Approaches for Protocol-Related Variability in Multisite Diffusion MRI Data
Liou, Kenny , Thomopoulos, Sophia I. , Reina, Julio E Villalon, Yoo, Hannah, Shuai, Yuhan , Chehrzadeh, Sasha, Arani, Arvin, Borowski, Bret, Reid, Robert I. , Weiner, Michael, Jahanshad, Neda , Thompson, Paul M., Nir, Talia M., Vemuri, Prashanthi , Jack, Clifford R , Reid, Robert I , Thomopoulos, Sophia I , Reina, Julio E Villalon, Arani, Arvin , Vemuri, Prashanthi , Jack, Clifford R. , Weiner, Michael W , Thompson, Paul M. , Nir, Talia M.

No container title available | July 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.07.737018 | PMID 42465495 Get It

Diffusion MRI (dMRI) enables assessment of white matter microstructural abnormalities in Alzheimer's disease (AD), and multisite datasets enable more robust modeling of non-biological variation that can confound analyses. The Alzheimer's Disease Neuroimaging Initiative (ADNI) includes over 10 dMRI protocols, necessitating robust methods to model protocol-related variability when pooling data. Here, we compared three harmonization approaches: (1) mixed-effects models, (2) ComBat-GAM, and (3) eHarmonize, a reference-based lifespan method. We assessed their ability to reduce protocol-related variability in diffusion tensor imaging fractional anisotropy (FA) and mean diffusivity (MD) while preserving associations with cognitive impairment (CI), and amyloid-beta (Aβ) and tau PET burden in 1,086 ADNI3/4 participants. All approaches yielded more closely aligned FA/MD distributions across protocols. Associations with clinical indicators of CI were highly consistent across approaches, whereas PET associations were less widespread and more variable. Overall, multiple strategies effectively modeled protocol-related variability while preserving AD-related associations.
Time to Effective Therapy and Mortality in Community-Acquired Legionella Pneumonia: A Multicenter Retrospective Cohort Study
Khattar, Georges , VanDolah, Hunter , Gotway, Michael, Ham, Kealy, Patel, R, Simner, Patricia J, Sen, Ayan, Skolnik, Aaron, Cartin‐Ceba, Rodrigo , Pulsipher, Aaron M. , Gotway, Michael B , Simner, Patricia J. , Vikram, Holenarasipur R.

Annals of the American Thoracic Society | July 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/annalsats/aaoag196 | PMID 42435403 Get It

Abstract Rationale Legionella species can cause severe community-acquired pneumonia requiring targeted antimicrobial therapy. The impact of time to effective Legionella-directed therapy on mortality is not well defined. Objectives To evaluate the association between time to effective Legionella-directed therapy and mortality in hospitalized patients with community-acquired Legionella pneumonia and to determine whether differences in treatment timing contribute to the excess mortality observed among immunocompromised patients. Methods A retrospective multicenter cohort study of adults hospitalized with laboratory-confirmed community-acquired Legionella pneumonia (2019–2025) was performed. Time from presentation to effective therapy (macrolide, fluoroquinolone, or doxycycline) was recorded. The primary outcome was 90-day mortality. Multivariable logistic regression analysis was performed, adjusting for age, SOFA-2 score (first 6 hours), and immunocompromised status. Secondary analyses included a 24-hour landmark Cox model for 90-day survival and multivariable logistic regression for 30-day mortality. Results Among 310 patients (median age 66.9 years, 44.8% immunocompromised), 90-day mortality was 17.4%. Every 6-hour delay in effective therapy was independently associated with increased 90-day mortality (adjusted OR per 6 hours: 1.11; 95% CI, 1.06–1.17; P &lt; 0.001). Delays &gt;24 hours were associated with worse 90-day survival (adjusted HR, 2.72; 95% CI, 1.65–4.77; P &lt; 0.001). Time to effective therapy was also independently associated with increased odds of 30 day mortality (adjusted OR per 6 hours: 1.06; 95% CI: 1.01-1.11, p = 0.024). Immunocompromised patients experienced longer delays (median, 7.1 versus 3.3 hours; P &lt; 0.001) and higher unadjusted 90-day mortality (22.3% versus 13.5%; P = 0.041), but immunocompromised status was not independently associated with mortality after adjusting for severity and treatment timing. Conclusion Longer time to effective Legionella-directed therapy was independently associated with increased mortality in a graded fashion. Delays were more common among immunocompromised patients, partially accounting for excess mortality in this group, suggesting that timely pathogen-directed therapy may represent a clinically important and potentially modifiable contributor to risk.
The ILLUMINATE natural history study in colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
Wade, Charles, Hayer, Stefanie N, Gelfand, Jeffrey M, Köhler, Wolfgang , Bergner, Christa-Caroline, Souza, Paulo Victor Sgobbi de, Finger, Elizabeth , Wolf, Nicole I. , Orthmann-Murphy, Jennifer L, Chmiela, Tomasz, Rajagovindan, Raj, McLaren, Donald G, Gaudreault, Francois, Mirescu, Christian, Raitcheva, Denitza, Meier, Andreas, Gray, David, Chavez, Juan, Kaufmann, Petra, Wszolek, Zbigniew K, Chmiela, Tomasz , Lynch, David S , Schöls, Ludger , Köhler, Wolfgang , Finger, Elizabeth C. , Wolf, Nicole I , Beerepoot, Shanice , Chmiela, Tomasz , Wade, Charles , Hayer, Stefanie N. , Gelfand, Jeffrey M. , Bergner, Caroline, Souza, Paulo Victor Sgobbi de , Orthmann‐Murphy, Jennifer , Rajagovindan, Raj, McLaren, Donald G. , Mirescu, Christian, Raitcheva, Denitza , Meier, Andreas , Kaufmann, Petra, Wszołek, Zbigniew K.

Brain Communications | July 11, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcag271 | PMID 42500553 Get It

Abstract Colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (CSF1R-ALSP) is a rare, fatal, autosomal-dominant neurodegenerative disorder caused by pathogenic CSF1R variants and characterized by progressive cognitive, neuropsychiatric, and motor dysfunction, white matter lesions on brain imaging, and white matter demyelination, swollen axons, and pigmented glial cells on pathology. Limited data regarding clinical, biofluid or radiological biomarkers of disease severity are available, and no clinical trial endpoints have yet been validated. The objectives of this first-of-its-kind, prospective, observational natural history study were to characterize the clinical trajectory of CSF1R-ALSP and to identify and evaluate key biomarkers and clinical endpoints indicative of disease severity and progression. ILLUMINATE (NCT05020743) was a multicentre, noninterventional natural history study of adults with CSF1R-ALSP and prodromal carriers of CSF1R variants. Participants were followed for up to 36 months, with clinical assessments, fluid biomarkers and volumetric MRI assessments of brain atrophy collected at screening and every 6 months. This study was terminated early (4 June 2025). The analyses reported here include data collected through 19 February 2025. Of 53 participants, 19 were prodromal and 34 were symptomatic (11 of whom had a history of haematopoietic stem cell transplant and 23 who did not). Mean participant age was 47.8 (standard deviation, 4.5) years, and 36.4% were female. Prodromal participants remained relatively stable over 36 months, with little change in neurological function, neurodegeneration biomarkers or radiological disease burden. Impaired neurological function, MRI characteristics of CSF1R-ALSP, and elevated NfL (neurofilament light chain; neurodegeneration biomarker) and GFAP (glial fibrillary acidic protein; astrogliosis biomarker) levels were more pronounced at baseline and often showed progression over time among symptomatic participants who had not previously received haematopoietic stem cell transplant compared with participants who had previously received haematopoietic stem cell transplant. Significant correlations were observed at baseline and longitudinally between MRI measures of brain atrophy and clinical outcome measures. Based on the fluid biomarkers, MRI measures, and clinical outcome assessments evaluated here, active neurodegeneration, widespread changes visualized on brain MRI, and impaired cognitive and motor function were observed in symptomatic patients with CSF1R-ALSP. The neurological impairment can be assessed using the Montreal Cognitive Assessment and Cortical Basal ganglia Functional Scale. Our data suggest that quantification of brain atrophy using MRI volumetry is a potential biomarker of disease severity and progression in CSF1R-ALSP. It is hoped that this report will contribute to the understanding of disease progression in CSF1R-ALSP and inform future drug development.
Peripheral and central inflammation associated with progressive cognitive decline in dementia with Lewy bodies
Swann, Peter, White, Simon R, Mak, Elijah , Surendranathan, Ajenthan, Jones, P Simon, Su, Li, Savulich, George , Kigar, Stacey, Mckeever, Anna, Fryer, Tim, Hong, Young T, Aigbirhio, Franklin I, Rowe, James B, Malpetti, Maura , Chouliaras, Leonidas , Mak, Elijah , Savulich, George , O'Brien, John Tiernan , Swann, Peter , Malpetti, Maura , White, Simon Richard , Surendranathan, Ajenthan , Jones, Peter Simon , Kigar, Stacey L. , McKeever, Anna , Fryer, Tim, Aigbirhio, Franklin I. , Rowe, James B.

Brain Communications | July 11, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcag274 | PMID 42529064 Get It

Abstract Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia, pathologically defined by the presence of Lewy bodies. Peripheral and central inflammation are increasingly recognized in DLB in clinical, post-mortem and animal studies. Finding clinically relevant biomarkers of inflammation in DLB will support the identification of novel pathways for disease-modifying therapies or use in clinical trials of immunomodulatory agents. Whilst there are cross-sectional studies of inflammation markers in DLB, there is limited evidence on the association between these markers and cognitive decline over time. Twenty participants with DLB underwent blood sampling for serum inflammatory markers, paired with PET imaging of the translocator protein (TSPO) and up to 4 years of longitudinal cognitive testing. Thirty participants with Alzheimer’s disease—comprising both Alzheimer’s dementia and/or mild cognitive impairment with biomarker evidence of amyloid pathology (AD/MCI+)—and 28 controls were also recruited for group comparisons. Data from 42 baseline cytokine immunoassays and TSPO PET were used as predictors of longitudinal cognitive scores in linear mixed-effects models. Partial least squares regression was used to test the association between peripheral and central inflammation. Using peripheral inflammatory markers as single predictors, we identified 14 associated with either a slower or faster rate of cognitive decline in DLB, whilst no single marker was predictive of decline in AD/MCI+. As many inflammatory markers were highly correlated, we used principal component analysis to identify a cytokine component associated with reduced cognitive decline in both DLB and AD/MCI+, that overlapped with the single markers identified in the previous analysis. A separate component was associated with cognitive decline in AD/MCI+ or DLB with Alzheimer’s dementia co-pathology (ascertained by amyloid PET). Widespread TSPO binding was associated with reduced cognitive decline in DLB, whilst a fronto-temporal pattern was associated with more rapid cognitive decline in both DLB and AD/MCI+. There were associations between peripheral cytokines and TSPO PET in AD/MCI+, but these were not significant in DLB. Overall, peripheral and central inflammation predicted cognitive decline in DLB. Specific patterns associated with both faster and slower rates of decline were identified. These profiles had both overlapping and contrasting associations when compared to AD/MCI+. Collectively, these data add to a body of evidence suggesting clinically relevant levels of inflammation in DLB. Future studies in larger, multi-site cohorts with multiple biomarker sampling points are required to understand the impact and dynamics of inflammation across all stages of the disease.
Attention reshapes the information dynamics of thalamic and cortical prediction-error learning
Äijälä, Juho , Jensen, Michael A. , Miller, Kai J. , Hermes, Dora , Blenkmann, Alejandro O. , Ince, Robin A. A. , Bekinschtein, Tristán , Vinck, Martin , Garagnani, Max , Jensen, Michael A , Vinck, Martin , Hermes, Dora , Canales‐Johnson, Andrés

No container title available | July 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.10.737794 Get It

Abstract Prediction errors (PEs) drive perceptual learning by updating internal models of the sensory environment, yet it remains unclear how attention reshapes their representation across distributed thalamocortical circuits. Using intracranial stereoelectroencephalography (sEEG) from 17 patients performing a roving auditory oddball task under attended and unattended conditions, we quantified PE encoding using mutual information and co-information to capture redundant and synergistic PE representations. Attention modulated PE encoding in both the thalamus and the temporal cortex, but with distinct informational dynamics. Thalamic encoding showed a stable reduction of PE information during distraction, consistent with state-dependent thalamocortical gating. In contrast, the temporal cortex expressed two opposing learning trajectories during attended listening that converged once attention was diverted, revealing distinct cortical learning regimes rather than a uniform attentional effect. Attention further reorganized the informational content of cortical PE representations by altering the balance between redundant and synergistic information. A biologically constrained neural network showed that attention-dependent changes in inhibition and long-range connectivity reproduced these dynamics through Hebbian learning. Together, these findings suggest that attention regulates predictive learning not simply by changing the strength of PE responses, but by reshaping how distributed thalamocortical circuits represent and integrate sensory evidence over time.
Association of Atomoxetine Discontinuation Patterns with CYP2D6 Phenotype in Children and Adolescents with Attention Deficit Hyperactivity Disorder
Brown, Jacob T. , Durgin, Elise N., Paetznick, Courtney , Deonovic, Benjamin, Yang, Laylia, Watson, David , Gregornik, David , Watson, David A, Bishop, Jeffrey R.

Journal of Child and Adolescent Psychopharmacology | July 11, 2026 | Volume: 36 | Issue: 8 | Pages: 493-499

10.1177/10445463261467214 | PMID 42433076 Get It

Aims: The primary aim of this study was to determine whether CYP2D6 phenotypes are associated with atomoxetine treatment outcomes in children and adolescents with attention-deficit hyperactivity disorder. Patients and Methods: Patients 21 years and younger with a known CYP2D6 genotype and a prescription for atomoxetine were included in this electronic health record review. The primary outcome was defined as discontinuation of atomoxetine due to a lack of efficacy or due to toxicity. CYP2D6 activity scores were adjusted to account for phenoconversion if patients were concomitantly taking a CYP2D6 inhibitor medication. Results: Of 108 patients that met inclusion criteria, including 13 poor, 30 intermediate, 61 normal, and 4 ultra-rapid CYP2D6 metabolizers after adjusting for phenoconversion. Normal/ultrarapid metabolizers were significantly more likely to discontinue atomoxetine due to lack of efficacy (subdistribution hazard ratio [sHR] = 1.9, p = 0.04), while poor/intermediate metabolizers were significantly more likely to stop due to toxicity (sHR 0.4, p = 0.03). A significant nonlinear effect of adjusted activity score on likelihood of discontinuation due to lack of efficacy ( p < 0.001) or toxicity ( p < 0.001) was identified, where higher CYP2D6 activity scores were associated with more discontinuation due to lack of efficacy and lower activity scores were associated with more discontinuation due to toxicity. When CYP2D6 genotype was available prior to prescribing atomoxetine in intermediate/poor metabolizers, lower median initial doses were observed (0.5 mg/kg/day) compared to those who underwent CYP2D6 genotyping after the initial atomoxetine prescription (0.8 mg/kg/day). Conclusion: Patients with normal or increased CYP2D6 phenotypes may be more likely to discontinue atomoxetine due to a lack of efficacy, while those with reduced function CYP2D6 phenotypes may be more likely to discontinue atomoxetine due to toxicity.